Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|August 3, 2021
Confidence intervals for exposure-adjusted rate differences in randomized trialsEmil Scosyrev, Abhijit Pethe
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 29, 2022
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studiesHironori Sagara, Peter D'Andrea, Ana-Maria Tanase, et al.
The European Respiratory Journal|August 26, 2017
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroidsEric D Bateman, Alfredo G Guerreros, Florian Brockhaus, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 19, 2022
Performance of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD: Evidence from Clinical and Online Patient Interaction StudiesFrancesco Patalano, Carolina Hache, Abhijit Pethe, et al.
Advances in Therapy|January 24, 2022
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for AsthmaDominic Brittain, Peter D'Andrea, Emilie Gruen, et al.
Clinical & Translational Immunology|March 22, 2021
Ligelizumab treatment for severe asthma: learnings from the clinical development programmeJordis Trischler, Ivan Bottoli, Reinhold Janocha, et al.
Respiratory Medicine|March 12, 2021
Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trialsEmil Scosyrev, Richard van Zyl-Smit, Huib Kerstjens, et al.
BMJ Open Respiratory Research|August 28, 2021
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studiesKenneth Chapman, Richard van Zyl-Smit, Jorge Maspero, et al.
The Lancet. Respiratory Medicine|July 13, 2020
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 studyHuib A M Kerstjens, Jorge Maspero, Kenneth R Chapman, et al.
The Lancet. Respiratory Medicine|July 13, 2020
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 studyRichard N van Zyl-Smit, Matthias Krüll, Christian Gessner, et al.
Pageof 2